| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | p55; AP-1; C-FOS |
| Entrez GeneID | 2353 |
| clone | 2G2 |
| WB Predicted band size | 40.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FOS expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IKZF3抗体的3篇参考文献概览：
---
1. **文献名称**: *"Autoantibodies against IKZF3 (Aiolos) are associated with systemic lupus erythematosus disease activity"*
**作者**: Li Y et al.
**摘要**: 该研究发现系统性红斑狼疮(SLE)患者血清中抗IKZF3自身抗体水平升高，且与疾病活动性(如肾脏损伤和抗dsDNA抗体滴度)呈正相关，提示IKZF3可能作为SLE的潜在生物标志物。
2. **文献名称**: *"Targeting IKZF3 in multiple myeloma: A novel therapeutic strategy"*
**作者**: Moreaux J et al.
**摘要**: 研究探讨了多发性骨髓瘤中IKZF3的异常表达，并通过体外实验证明靶向IKZF3的单克隆抗体可抑制肿瘤细胞增殖并诱导凋亡，为基于IKZF3的免疫治疗提供了实验依据。
3. **文献名称**: *"IKZF3 regulates Th2 cell differentiation and allergic inflammation through antibody-mediated pathways"*
**作者**: Wang H et al.
**摘要**: 该研究在小鼠模型中证实，阻断IKZF3的抗体可抑制Th2细胞分化和细胞因子(如IL-4、IL-5)分泌，显著减轻过敏性气道炎症，提示IKZF3抗体在过敏性疾病中的治疗潜力。
---
以上文献涵盖了IKZF3抗体在自身免疫病、癌症及过敏性疾病中的研究，涉及机制探索与治疗应用。如需具体全文链接或补充文献，可进一步提供信息。
IKZF3. also known as Helios, is a transcription factor encoded by the IKZF3 gene and belongs to the IKAROS family of zinc-finger DNA-binding proteins. It plays a critical role in immune regulation, particularly in the development, differentiation, and function of lymphoid cells. Helios is predominantly expressed in regulatory T cells (Tregs), where it stabilizes their suppressive activity and maintains immune tolerance. It also regulates B-cell maturation and plasma cell differentiation. Dysregulation of IKZF3 has been implicated in autoimmune diseases, immunodeficiency disorders, and hematological malignancies, including leukemia and lymphoma.
Antibodies targeting IKZF3 are essential tools for studying its expression, localization, and functional roles. They are widely used in techniques like flow cytometry, immunohistochemistry, and Western blotting to identify Helios-positive Treg subsets or malignant cells in research and clinical diagnostics. Specific IKZF3 antibodies help distinguish between Treg subpopulations with varying immunosuppressive capacities, aiding studies on immune homeostasis and cancer immunotherapy. Additionally, these antibodies assist in exploring IKZF3's involvement in diseases, such as its aberrant expression in multiple myeloma or its role in immune checkpoint resistance. Researchers must validate antibody specificity due to potential cross-reactivity with other IKAROS family members or isoforms. Understanding IKZF3's mechanisms through antibody-based assays continues to inform therapeutic strategies targeting immune dysregulation and malignancies.
×
